Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDX-1097
- Development stage
- Unknown
- Lead developer
- HaemaLogiX
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KappaMab (MDX-1097) is a chimeric IgG1κ monoclonal antibody developed for the treatment of kappa light chain-restricted multiple myeloma and related B-cell malignancies. It specifically targets the kappa myeloma antigen (KMA), a membrane-bound form of free kappa light chain found on malignant plasma cells in kappa-type multiple myeloma and some lymphomas, but not on normal B cells or other healthy tissues. By binding to KMA, KappaMab induces immune-mediated killing of cancer cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The drug has shown synergistic effects when combined with lenalidomide and dexamethasone in clinical trials for relapsed/refractory multiple myeloma. Developed by HaemaLogiX, it has demonstrated a favorable safety profile in Phase 1/2 studies and is being further evaluated in combination regimens.
- Other names
- KappaMabKM
02
Targets
Immunoglobulin light chain
Beyond the preview
Go deeper on MDX-1097.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDX-1097.